Login / Signup

Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice.

Ulf LindströmTor OlofssonSara WedrénIlia QirjazoJohan Askling
Published in: Arthritis research & therapy (2019)
Less than half of patients with AS will remain on their first TNFi after 5 years, but most are still on a biologic. While patients remaining on treatment with their first TNFi appear to be able to reduce the dose over time, a large proportion cycle through several biologics, and 1/3 have no anti-rheumatic treatment after 5 years. This indicates the importance of thorough follow-up programs as well as a need for alternative therapeutic options.
Keyphrases
  • ankylosing spondylitis
  • clinical practice
  • chronic kidney disease
  • end stage renal disease
  • public health
  • systemic lupus erythematosus
  • ejection fraction
  • newly diagnosed
  • case report
  • prognostic factors